IP Library › Granted Patent US 8,871,716
Granted Patent B2
US 8,871,716 · App. 13/095,763 · Granted Oct 28, 2014

Use of antimicrobial peptides in regeneration of skin cells

Inventors: Sun-Chang Kim (Daejeon, KR); Da-Jung Kim (Daejeon, KR); Su-A Jang (Daejeon, KR); Bong Hyun Sung (Daejeon, KR); Ki-Jung Lim (Daejeon, KR); Ju-Ri Shin (Daejeon, KR); Young Woong Lee (Daejeon, KR)
Assignees: Korea Advanced Institute of Science and Technology; Intelligent Synthetic Biology Center
A61K38/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,716
App. No.
13/095,763
Granted
Oct 28, 2014
Kind
B2
Abstract

Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.

Claims (6)

1. A method of regenerating skin cells, the method comprising:

applying to an injured skin a composition promoting skin cell migration and thereby regenerating skin cells in the injured skin, the composition comprising a peptide having an amino acid sequence of SEQ ID NO. 1.

2. The method according to claim 1 , wherein the peptide is amidated at the C-terminal end thereof.

3. The method according to claim 1 , wherein the peptide is subjected to an in vivo salt concentration from 100 to 200 mM.

4. The method according to claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier, excipient or diluents.

5. The method according to claim 1 , wherein the peptide is present at a concentration of from 0.5 to 2 μM.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYANCE OF ASSIGNMENT PREVIOUSLY RECORDED ON REEL 029558 FRAME 0078. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT IN WHICH 50% OF ASSIGNOR'S INTEREST WAS ASSIGNED TO ASSIGNEE TO FORM CO-OWNERSHIP BETWEEN ASSIGNOR AND ASSIGNEE. Recorded Aug 12, 2013
From: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
To: INTELLIGENT SYNTHETIC BIOLOGY CENTER
Reel/Frame 031004/0573 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2013
From: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
To: INTELLIGENT SYNTHETIC BIOLOGY CENTER
Reel/Frame 029558/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2011
From: KIM, SUN-CHANG; KIM, DA-JUNG; JANG, SU-A; SUNG, BONG HYUN; LIM, KI-JUNG; SHIN, JU-RI; LEE, YOUNG WOONG
To: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 026517/0560 →
Priority Claims (1)
KR 10-2010-0098259 · Oct 8, 2010 · national
Continuity (2)
Continuation PCTKR2010009558 · Dec 30, 2010
Related Publication 20120088733A1 · Apr 12, 2012